Group 1 - The company announced a restrictive stock incentive plan aimed at promoting the implementation of its long-term strategy, granting 704,000 shares to 54 executives and key personnel, representing approximately 0.79% of the total share capital, with an exercise price of 38.66 yuan per share and performance assessment targets based on revenue for 2025 and 2026 [1][2] - For 2024, the company expects a significant decline in net profit, projected to drop by 44.5% to 55.6% year-on-year, primarily due to a decrease in revenue influenced by inventory destocking in the U.S. market, although there has been a quarter-on-quarter improvement in Q3 2024 [1][2] - The performance assessment targets for the restrictive stock plan are set at no less than 1.01 billion yuan for 2025 and 1.21 billion yuan for 2026, indicating a growth expectation of 19.8% [2] Group 2 - The stock incentive plan is seen as a positive signal for the company's long-term strategy, despite the downward adjustment of revenue forecasts for 2024, 2025, and 2026 to 801 million, 962 million, and 1.129 billion yuan respectively [3] - The company has reached a cooperation agreement with RH Company, expanding its distribution area to include Canada and increasing the range of products related to lung disease, which is expected to enhance market share in the U.S. [2][3]
怡和嘉业(301367)：推出限制性股票激励计划 预计营收将重回增长